Provided by Tiger Trade Technology Pte. Ltd.

Intellia Therapeutics

12.21
-0.5300-4.16%
Post-market: 12.250.0400+0.33%19:46 EDT
Volume:4.93M
Turnover:61.02M
Market Cap:1.71B
PE:-3.65
High:12.82
Open:12.50
Low:12.19
Close:12.74
52wk High:28.25
52wk Low:7.95
Shares:140.00M
Float Shares:137.56M
Volume Ratio:1.61
T/O Rate:3.59%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3456
EPS(LYR):-3.8100
ROE:-55.44%
ROA:-30.14%
PB:2.35
PE(LYR):-3.20

Loading ...

Cathie Wood’s ARK Investment buys 204K shares of Intellia Therapeutics today

TIPRANKS
·
7 hours ago

Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (COLL), Revolution Medicines (RVMD) and Intellia Therapeutics (NTLA)

TIPRANKS
·
Yesterday

Intellia Therapeutics Price Target Maintained with a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
Yesterday

U.S. Stocks on the MOVE-Best Buy, Peloton, Apple

Reuters
·
Yesterday

Wedbush Adjusts Intellia Therapeutics Price Target to $13 From $12, Maintains Neutral Rating

MT Newswires Live
·
Sep 08

U.S. Stocks on the MOVE-Sigma Lithium, Shake Shack, Novartis

Reuters
·
Sep 08

Intellia Rises After FDA Grants Fast-Track Status to Its Treatment for Rare Disease

Reuters
·
Sep 08

Intellia Therapeutics Shares up 4.9% Premarket After FDA Accepts to Fast-Track Co's Treatment for a Rare Swelling Disorder

THOMSON REUTERS
·
Sep 08

Intellia Therapeutics announces FDA acceptance of lonvo-z BLA

TIPRANKS
·
Sep 08

Intellia Says FDA Accepts Lonvo-Z BLA for Hereditary Angioedema, Grants Priority Review

Reuters
·
Sep 08

Intellia Therapeutics, - FDA Accepts Bla for Lonvo-Z and Grants Priority Review with Pdufa Date March 10, 2027

THOMSON REUTERS
·
Sep 08

Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-Z) for Hereditary Angioedema (Hae)

THOMSON REUTERS
·
Sep 08

Intellia Therapeutics, - FDA not Planning to Hold Advisory Committee for Lonvo-Z Application

THOMSON REUTERS
·
Sep 08

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Intellia Therapeutics (NTLA) and Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Sep 08

Intellia Therapeutics Secures Major Non-Dilutive Loan Financing

TIPRANKS
·
Sep 05

Intellia Awards 163,100 RSUs to 41 New Employees Under Inducement Plan

Reuters
·
Sep 05

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Sep 05

Intellia Therapeutics Secures $400 Million Senior Secured Term Loan Facility with OrbiMed

Reuters
·
Sep 04

Intellia Therapeutics, - Additional $100 Mln Available Subject to Mutual Agreement During Five-Year Term

THOMSON REUTERS
·
Sep 04

Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference

GlobeNewswire
·
Sep 04